+1-888-308-5802      . .

Aimmune’s PALFORZIA obtains EC’s approval for treating peanut allergies

Author : Saipriya Iyer | Published Date : 2020-12-22 

Aimmune’s PALFORZIA obtains EC’s approval for treating peanut allergies

In recent developments, U.S.-based biopharmaceutical company Aimmune Therapeutics Inc. has reportedly received approval from the European Commission (EC) for using its oral immunotherapy, PALFORZIA to treat individuals with peanut allergy.

For the uninitiated, PALFORZIA is a biologic drug that is administered with a systematic dosage approach based on oral immunotherapy (OIT). The process involves the initial ingestion of the specific allergenic proteins in small quantities followed by a gradual increment in the amount to mitigate allergic reactions to the allergen. Furthermore, the drug is produced from a defatted powder of Arachis hypogaea L and is indicated in patients between the age of 4 to 17 years.

The recent development comes after two successful phases 3 clinical trials of the drug, namely Artemis and Palisade, cited sources with relevant information. The oral immunotherapy, in both the trials, met the primary objective and outperformed the placebo results.

President and CEO of Aimmune Therapeutics, Andrew Oxtoby was reported saying that the European Commission’s approval of the treatment is a significant milestone for the company. The company will now focus on launching the product in the United Kingdom and Germany in May 2021, he added.

Meanwhile, Greg Behar, CEO of Nestlé Health Science S.A., commented that the EC approval is the first treatment approved for peanut allergy in the European Union.

Reportedly, around 17 million people across Europe are affected by food allergies, among which peanut allergy is of the highest prevalence. Approximately 1.6% of European children develop the allergy at an early stage and are subject to life-threatening symptoms.

About Aimmune Therapeutics Inc.

Aimmune Therapeutics is a subsidiary of Nestlé Health Science S.A that functions as a clinical-stage biopharmaceutical firm. The California-headquartered organization focuses on commercializing and developing treatments for potentially life-threatening food allergies as well as other food-mediated ailments, primarily gastrointestinal conditions.

Source credits –

https://www.businesswire.com/news/home/20201220005027/en/European-Commission-Approves-Aimmune%E2%80%99s-PALFORZIA%C2%AE-as-First-Ever-Treatment-for-Peanut-Allergy-in-the-EU

About Author

Saipriya Iyer . .

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

OPPO records 22% growth in Q1 2022 under “Made in India” initiative

OPPO records 22% growth in Q1 2022 under “Made in India” initiative

Published Date: 2022-06-21         Author: Saipriya Iyer

Global smartphone company OPPO has reportedly dominated the first quarter of 2022 with a 22% y-o-y growth rate under its “Made in India” initiative. For those unaware, approximately 190 million smartphones "Made in India" were shipped in 2021, owing to the support from numer... Read More>>

Audio content platform NOICE raises USD 22 million in Series A funding

Audio content platform NOICE raises USD 22 million in Series A funding

Published Date: 2022-04-22         Author: Saipriya Iyer

NOICE, an Indonesian audio content startup, has reportedly raised USD 22 million in Series A funding from Northstar, as well as existing investors Kinesys and Alpha JWC Go-Ventures. The funds will be used to advance technology that aids in the adaptation of stories from local writers into audio f... Read More>>

Chinese oil major CNOOC planning to secure USD 4.4 Bn in Shanghai IPO

Chinese oil major CNOOC planning to secure USD 4.4 Bn in Shanghai IPO

Published Date: 2022-04-12         Author: Saipriya Iyer

CNOOC Ltd., China’s major offshore oil producer, is reportedly planning to raise around USD 4.4 billion (28.08 billion yuan) during its stock market debut in Shanghai, marking it as one of the largest public offerings in mainland China. In a sales prospectus, the company stated that the fun... Read More>>

© 2022 Fractovia. All Rights Reserved